title: Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.
abstract: Tumor necrosis factor (TNF) alpha is a major proinflammatory cytokine involved in the immune response in inflammatory bowel disease (IBD). Anti-TNF drugs such as infliximab and adalimumab are used to treat IBD; however, approximately 30% of patients do not respond to treatment. Individual genetic differences could contribute to lack of efficacy. Genetic studies have tried to uncover the factors underlying differences in response, however, knowledge remains limited, and the results obtained should be validated, so that pharmacogenetic information can be applied in clinical practice. In this review, we gather current knowledge in the pharmacogenetics of anti-TNF drugs in patients with IBD. We observed a connection between the major genes described as possible predictors of response to anti-TNF drugs in IBD and the cytokines and molecules involved in the T helper (Th) 17 pathway.
authors: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IP), Madrid 28006, Spain. rociomaria.prieto@gmail.com.|Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Madrid 28029, Spain. rociomaria.prieto@gmail.com.
authors: Rocío
authors: R
authors: Prieto-Pérez
authors: Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. balmoguera@hotmail.com.
authors: Berta
authors: B
authors: Almoguera
authors: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IP), Madrid 28006, Spain. teresacabaleiro@hotmail.com.|Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Madrid 28029, Spain. teresacabaleiro@hotmail.com.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28006, Spain. teresacabaleiro@hotmail.com.
authors: Teresa
authors: T
authors: Cabaleiro
authors: Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. hakonarson@email.chop.edu.
authors: Hakon
authors: H
authors: Hakonarson
authors: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IP), Madrid 28006, Spain. francisco.abad@salud.madrid.org.|Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Madrid 28029, Spain. francisco.abad@salud.madrid.org.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28006, Spain. francisco.abad@salud.madrid.org.
authors: Francisco
authors: F
authors: Abad-Santos
mesh_terms: D000068879:Adalimumab / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D007107:Immune System / Q000276:immunology / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D000069285:Infliximab / Q000494:pharmacology / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D058504:Th17 Cells / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab
keywords: adalimumab; inflammatory bowel disease; infliximab; pharmacogenomics; polymorphisms